Overactive Bladder Medications in Atrial Fibrillation

Understanding the Risks of OAB Medications in AFib

• Most traditional OAB medications have antimuscarinic properties that can potentially prolong the QT interval, increasing the risk of torsades de pointes in patients with atrial fibrillation, and should be used with caution in patients with AFib, especially those taking other QT-prolonging medications such as amiodarone, dofetilide, or quinidine 1, 2

Medication-Specific Considerations for AFib Patients

• If mirabegron is contraindicated or ineffective, antimuscarinic agents may be considered with careful monitoring, as they can potentially worsen arrhythmias in patients with atrial fibrillation 1

Monitoring and Management

• Review current AFib medications to identify potential drug interactions, and check baseline ECG to assess QT interval, especially if considering antimuscarinic agents, as recommended by the American Heart Association 1, 3
• Monitor heart rate and rhythm regularly, especially during the first few weeks of treatment, to minimize the risk of adverse effects in patients with atrial fibrillation 3